INKT — MiNK Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1840229 ·
Last close
$12.18
Market Cap
$62.15M
52W High
$16.93
52W Low
$8.48
ADV30
12,550
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,216,894 | -3,128,201 | 9,615,242 | 8,806,977 | 23,643,538 |
| Mar 2026 | 0 | — | -2,881,787 | -2,742,368 | 10,376,972 | 9,525,676 | 23,062,961 |
| Dec 2025 | 0 | — | -3,276,559 | -2,602,103 | 14,238,842 | 13,360,340 | 28,466,501 |
| Sep 2025 | 0 | — | -2,989,673 | -2,887,709 | 14,963,665 | 14,281,212 | 28,476,647 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,316,889
Investing CF
$0
Financing CF
$12,620,491
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.98
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-159,418,363
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-12,836,325
Pretax Income TTM
$-12,469,931
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -12,487,304 | -12,494,260 | 14,238,842 | 28,466,501 | -14,227,659 | -5,925,168 |
| Dec 2024 | 0 | -10,650,239 | -10,784,802 | 5,720,813 | 25,306,695 | -19,585,882 | -9,555,476 |
| Dec 2023 | 0 | -22,921,105 | -22,457,859 | 4,552,281 | 22,607,730 | -18,055,449 | -15,762,512 |
| Dec 2022 | 0 | -30,949,278 | -27,991,212 | 21,471,602 | 21,872,905 | -401,303 | -18,866,843 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.65
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EXOZ | EXOZYMES INC. | $57.96M | $6.24 | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $68.20M | $4.90 | — |
| INMB | Inmune Bio, Inc. | $56.34M | $2.03 | — |
| KLRS | Kalaris Therapeutics, Inc. | $69.51M | $2.92 | — |
| IMA | ImageneBio, Inc. | $53.69M | $4.72 | — |
News headlines (Yahoo Finance, 1h cache)
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript
2026-08-14 03:28 · Yahoo
MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ...
2026-08-13 23:07 · Yahoo
MiNK Therapeutics Q2 Earnings Call Highlights
2026-08-13 16:04 · Yahoo
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
2026-08-06 12:19 · Yahoo
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
2026-05-28 13:04 · Yahoo
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
2026-05-20 15:07 · Yahoo
We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate
2026-05-18 10:24 · Yahoo
MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...
2026-05-15 23:01 · Yahoo
MiNK Therapeutics Q1 Earnings Call Highlights
2026-05-15 14:12 · Yahoo
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
2026-05-15 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.